Renin-Angiotensin System - other agents (sparsentan, atrasentan)
Customize your policy alerts
Sign up for allcareadvantage Policy 134.1 alerts
Get alerted when Policy 134.1 changes without checking for updates manually.
Monitor payer policy activity
Prior authorization policy for coverage of renin-angiotensin system - other agents (Filspari/sparsentan and Vanrafia/atrasentan) for adults with primary IgA nephropathy (IgAN) at risk; governs prescribers, renal specialists, and payer reviewers for AllCare Advantage members.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.